AR060448A1 - Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo - Google Patents
Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazoInfo
- Publication number
- AR060448A1 AR060448A1 ARP070101581A ARP070101581A AR060448A1 AR 060448 A1 AR060448 A1 AR 060448A1 AR P070101581 A ARP070101581 A AR P070101581A AR P070101581 A ARP070101581 A AR P070101581A AR 060448 A1 AR060448 A1 AR 060448A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nucleotides
- syk
- region
- mrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
Se proporciona interferencia de ARN para la inhibicion de la expresion de ARNm de tirosina quinasa de bazo (Syk, segun sus siglas en inglés), en particular, para tratar pacientes que tienen una afeccion inflamatoria relacionada con Syk o que se encuentran en riesgo de desarrollar una afeccion inflamatoria relacionada con Syk tal como conjuntivitis alérgica, inflamacion acular, dermatitis, rinitis, asma, alergia o enfermedad de células cebadas. Reivindicacion 1: El uso de ARN de interferencia para la manufactura de un medicamento para atenuar la expresion de ARNm de Syk de un sujeto, que comprende: administrar al sujeto una composicion que comprende una cantidad eficaz de ARN de interferencia (iRNA) que tiene una longitud de 19 a 49 nucleotidos y un portador aceptable para uso farmacéutico, comprendiendo el ARN de interferencia una region seleccionada del grupo formado por: una region de por lo menos 13 nucleotidos contiguos que tiene por lo menos 90% de complementariedad entre secuencias con, o por lo menos 90% de identidad de secuencias con, los 13 nucleotidos penultimos del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; una region de por lo menos 14 nucleotidos contiguos que tiene por lo menos 85% de complementariedad entre secuencias a, o por lo menos 85% de identidad de secuencias con, los penultimos 14 nucleotidos del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; y una region de por lo menos 15, 16, 17 o 18 nucleotidos contiguos que tiene por lo menos 80% de complementariedad entre secuencias a, o por lo menos 80% de identidad de secuencias con, los penultimos 15, 16, 17 o 18 nucleotidos, respectivamente, del extremo 3' de un ARNm correspondiente a cualquiera de SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 40; donde la expresion de ARNm de Syk es atenuada de ese modo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79184706P | 2006-04-13 | 2006-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR060448A1 true AR060448A1 (es) | 2008-06-18 |
Family
ID=38610402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101581A AR060448A1 (es) | 2006-04-13 | 2007-04-13 | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo |
Country Status (13)
Country | Link |
---|---|
US (4) | US8048863B2 (es) |
EP (3) | EP2662446A3 (es) |
JP (1) | JP2009533475A (es) |
KR (1) | KR20080110900A (es) |
CN (2) | CN101443020A (es) |
AR (1) | AR060448A1 (es) |
AU (2) | AU2007238027B2 (es) |
BR (1) | BRPI0709506A2 (es) |
CA (1) | CA2649138C (es) |
MX (2) | MX345954B (es) |
TW (2) | TW200808360A (es) |
WO (1) | WO2007121347A2 (es) |
ZA (1) | ZA200808744B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101815536A (zh) * | 2007-10-01 | 2010-08-25 | 爱尔康研究有限公司 | 自补aav介导的干扰rna分子递送以治疗或预防眼病 |
WO2009144230A1 (en) * | 2008-05-26 | 2009-12-03 | Universität Zürich | Protamine/rna nanoparticles for immunostimulation |
AU2009330458B2 (en) * | 2008-12-22 | 2013-08-22 | Otonomy, Inc. | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
EP2865758A1 (en) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
CN104805085A (zh) * | 2014-01-29 | 2015-07-29 | 江苏命码生物科技有限公司 | 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用 |
EP3241903A4 (en) * | 2014-12-29 | 2018-07-04 | Bonac Corporation | Composition containing nucleic acid molecule stably |
US10888391B2 (en) | 2015-05-29 | 2021-01-12 | Ablacon Inc | Optical force sensing assembly for an elongated medical device |
EP3369816B1 (en) | 2015-10-30 | 2024-03-13 | Toray Industries, Inc. | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene |
BR102018001541B1 (pt) | 2018-01-24 | 2021-05-11 | Universidade Federal Do Rio Grande Do Sul | composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5360720A (en) | 1993-10-08 | 1994-11-01 | Alcon Laboratories, Inc. | Method of preparing human conjunctival mast cells for mast cell stabilization assays |
US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
JPH11507824A (ja) * | 1995-06-07 | 1999-07-13 | ユニバーシティー・オブ・ペンシルバニア | 食作用を阻害する方法 |
WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
EP2157191B1 (en) * | 2002-10-01 | 2013-12-25 | Epigenomics AG | Use of PITX2 nucleic acids for the improved treatment of breast cell proliferative disorders |
EP2278005A3 (en) * | 2002-11-14 | 2012-05-23 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20060275762A1 (en) * | 2002-11-22 | 2006-12-07 | Bio- Think Tank Co., Ltd., | Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp |
AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
CA2531069A1 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
WO2005049838A2 (en) * | 2003-11-14 | 2005-06-02 | Yale University | Syk-targeted nucleic acid interference |
GB0404209D0 (en) | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
WO2005085443A2 (en) * | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
EP1904649A2 (en) * | 2005-07-18 | 2008-04-02 | Epigenomics AG | Compositions and methods for cancer diagnostics comprising pan-cancer markers |
ES2562428T3 (es) * | 2005-12-15 | 2016-03-04 | Rigel Pharmaceuticals, Inc. | Inhibidores de cinasa y sus usos |
UY31267A1 (es) | 2007-08-03 | 2009-01-05 | Alcon Res Ltd | Inhibición del pasaje de senalización del tnfa relacionada con arni para el tratamiento de la angiogénesis ocular |
-
2007
- 2007-04-12 TW TW096112900A patent/TW200808360A/zh unknown
- 2007-04-12 TW TW102118618A patent/TW201336514A/zh unknown
- 2007-04-13 BR BRPI0709506-6A patent/BRPI0709506A2/pt not_active IP Right Cessation
- 2007-04-13 MX MX2013005786A patent/MX345954B/es unknown
- 2007-04-13 CN CNA2007800131881A patent/CN101443020A/zh active Pending
- 2007-04-13 EP EP20130176714 patent/EP2662446A3/en not_active Withdrawn
- 2007-04-13 CA CA2649138A patent/CA2649138C/en active Active
- 2007-04-13 EP EP07760636A patent/EP2004240A4/en not_active Ceased
- 2007-04-13 US US12/296,621 patent/US8048863B2/en active Active
- 2007-04-13 MX MX2008013068A patent/MX2008013068A/es active IP Right Grant
- 2007-04-13 AR ARP070101581A patent/AR060448A1/es unknown
- 2007-04-13 CN CN2010105249510A patent/CN101972483A/zh active Pending
- 2007-04-13 AU AU2007238027A patent/AU2007238027B2/en active Active
- 2007-04-13 JP JP2009505636A patent/JP2009533475A/ja active Pending
- 2007-04-13 EP EP16199741.6A patent/EP3156486A3/en not_active Withdrawn
- 2007-04-13 WO PCT/US2007/066619 patent/WO2007121347A2/en active Application Filing
- 2007-04-13 KR KR1020087027710A patent/KR20080110900A/ko not_active Application Discontinuation
-
2008
- 2008-10-14 ZA ZA200808744A patent/ZA200808744B/xx unknown
-
2011
- 2011-06-30 US US13/172,964 patent/US8865671B2/en active Active
-
2013
- 2013-07-17 AU AU2013207601A patent/AU2013207601B2/en active Active
-
2014
- 2014-05-05 US US14/270,174 patent/US9371529B2/en active Active
-
2016
- 2016-05-17 US US15/156,430 patent/US20160257963A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101443020A (zh) | 2009-05-27 |
US20090324507A1 (en) | 2009-12-31 |
EP3156486A2 (en) | 2017-04-19 |
EP2004240A4 (en) | 2010-12-15 |
EP2662446A2 (en) | 2013-11-13 |
EP3156486A3 (en) | 2017-07-12 |
TW201336514A (zh) | 2013-09-16 |
CN101972483A (zh) | 2011-02-16 |
US20110288157A1 (en) | 2011-11-24 |
ZA200808744B (en) | 2009-12-30 |
EP2004240A2 (en) | 2008-12-24 |
US8865671B2 (en) | 2014-10-21 |
MX345954B (es) | 2017-02-16 |
BRPI0709506A2 (pt) | 2011-07-19 |
AU2007238027B2 (en) | 2013-08-15 |
WO2007121347A3 (en) | 2008-12-04 |
US9371529B2 (en) | 2016-06-21 |
WO2007121347A2 (en) | 2007-10-25 |
JP2009533475A (ja) | 2009-09-17 |
EP2662446A3 (en) | 2014-04-02 |
US8048863B2 (en) | 2011-11-01 |
US20160257963A1 (en) | 2016-09-08 |
TW200808360A (en) | 2008-02-16 |
CA2649138C (en) | 2018-04-03 |
AU2007238027A1 (en) | 2007-10-25 |
US20140357695A1 (en) | 2014-12-04 |
AU2013207601B2 (en) | 2016-11-17 |
CA2649138A1 (en) | 2007-10-25 |
KR20080110900A (ko) | 2008-12-19 |
MX2008013068A (es) | 2008-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR060448A1 (es) | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo | |
PE20190443A1 (es) | Moleculas de acido nucleico para la reduccion de arnm de papd5 o papd7 para tratar la infeccion por hepatitis b | |
UY32085A (es) | Inhibidores de cinasa y métodos para su uso | |
ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
AR061064A1 (es) | Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfa | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
EA201100427A1 (ru) | Гетероциклические ингибиторы киназы | |
BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
NI200900106A (es) | Inhibidores de la actividad de la akt. | |
CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
DOP2013000054A (es) | Imidazopiridazinas sustituidas | |
ECSP10010559A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
BR112012014760A2 (pt) | "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso" | |
CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
CR10166A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania | |
CR10609A (es) | Moduladores de benzofuro-y benzotienopirimidina del receptor h4 de histamina | |
BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
WO2007143557A3 (en) | Compounds and methods for treating mammalian gastrointestinal parasitic infections | |
UY32312A (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
CL2020002563A1 (es) | Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |